Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126615
Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Dear Editor, Thrombocytopenia is a common complication seen in patients
with chronic liver disease, precluding or interfering invasive diagnostic
and therapeutic procedures. Etiology is multifactorial,
including hypersplenism, bone marrow suppression by HCV and
a possible reduction in the level or activity of the hematopoietic
growth factor thrombopoietin (TPO)(1). In addition to thrombocytopenia,
functional platelet defects has been suggested. Romiplostim
(Nplate®, Amgen Inc, Thousands Oaks, Calif) is a new
thrombopoietin receptor agonist indicated for the treatment of
thrombocytopenia in patients with chronic immune thrombocytopenic
purpura who have had an insufficient response to corticosteroids,
immunoglobulin or splenectomy (2). It has been not
tested in chronic liver disease until now. Another thrombopoietin
receptor agonist, eltrombopag (3), has been tested in chronic liver
disease undergoing an elective invasive procedure. Although
results were satisfactory in terms of platetelet count and avoidance
of platelet transfusions, the trial was early stopped due to the
observed incidence of portal vein thrombosis in the study group
(4). We report a case of a Jehovah’s Witness that could successfully
managed with romiplostim use...
Descripció
Letters to the Editor
Matèries
Matèries (anglès)
Citació
Citació
CASTELLOTE ALONSO, José, GIRBAU, Anna, ARAJOL, Claudia, XIOL QUINGLES, Xavier. Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure. _Revista Española de Enfermedades Digestivas_. 2011. Vol. 103, núm. 10, pàgs. 556-556. [consulta: 4 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/126615]